Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTRADIOL VALERATE ESTRADIOL VALERATE DIENOGEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTRADIOL VALERATE ESTRADIOL VALERATE DIENOGEST.
DIETHYLSTILBESTROL vs ESTRADIOL VALERATE; ESTRADIOL VALERATE; DIENOGEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Estradiol valerate is a prodrug of estradiol, an estrogen receptor agonist. Dienogest is a progestin with partial antiandrogenic activity, acting as a progesterone receptor agonist with antiovulatory and endometrial antiproliferative effects.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
One tablet daily containing estradiol valerate 2 mg and dienogest 3 mg (oral).
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Estradiol valerate: Terminal half-life is approximately 13-14 hours for estradiol. Dienogest: Terminal half-life is about 10-11 hours. The combination allows for once-daily dosing with sustained hormone levels.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Estradiol valerate and dienogest: Urinary excretion accounts for approximately 50-60% of total clearance, primarily as glucuronide conjugates of estradiol and dienogest metabolites. Fecal/biliary excretion accounts for 30-40% of dienogest and its metabolites. For estradiol valerate, about 30% of metabolites are excreted in bile and feces.
Category C
Category D/X
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."